| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg | |||
| Other Sizes |
| Targets |
The molecular targets of this flavonoid are not fully characterized. Flavonoids are known to interact with multiple targets, including the GABA-A receptor complex. Its anxiolytic effects are thought to be mediated through the benzodiazepine binding site on the GABA-A receptor.
|
|---|---|
| ln Vitro |
This compound exhibits inhibitory activity against various cancer cell lines, including NCI-H460 (lung), MCF-7 (breast), and A375-C5 (melanoma) cells. It also possesses anti-Trypanosoma and anti-Leishmania (anti-parasitic) activities.
|
| ln Vivo |
In vivo, 3-Hydroxy-7-methoxyflavone has demonstrated anti-anxiety effects in standard behavioral models such as the elevated plus maze. Its structural diversity allows it to serve as a lead compound for developing therapies for anxiety disorders.
|
| Enzyme Assay |
Not specified for this compound. General flavonoid binding assays involve competitive binding to the benzodiazepine site of GABA-A receptors using radiolabeled flunitrazepam or other ligands in brain membrane preparations.
|
| Cell Assay |
Not specified for this compound. Standard cell-based assays for anti-cancer activity include MTT or CCK-8 assays, where cells are treated with the compound for 24-72 hours, and cell viability is measured by absorbance.
|
| Animal Protocol |
In vivo anxiolytic activity is commonly evaluated using the elevated plus maze test in rodents. Animals are administered the compound orally or intraperitoneally, and the time spent in open arms versus closed arms is recorded as a measure of anxiety-like behavior.
|
| ADME/Pharmacokinetics |
Metabolism / Metabolites
Known metabolites of 3-hydroxy-7-methoxyflavonoids include (2S,3S,4S,5R)-3,4,5-trihydroxy-6-(7-methoxy-4-oxo-2-phenylchromene-3-yl)oxaoxane-2-carboxylic acid. Pharmacokinetic data for this compound are not well documented. As a flavonoid, it is expected to undergo extensive phase II metabolism (glucuronidation and sulfation) and may have moderate oral bioavailability. |
| Toxicity/Toxicokinetics |
Toxicological data for 3-Hydroxy-7-methoxyflavone are limited. In general, flavonoids are considered safe with low acute toxicity. No significant adverse effects have been reported at standard research dosages in animal models.
|
| References | |
| Additional Infomation |
3-Hydroxy-7-methoxyflavonoids are hydroxyflavones. It has been reported that Siberian pine contains 7-methoxyflavonols, and relevant data are available for reference.
This compound is primarily a research chemical used in pharmacological studies. It has not been approved for clinical use. Its mechanism of action likely involves GABA-A receptor modulation, but further studies are needed to confirm direct binding. |
| Molecular Formula |
C16H12O4
|
|---|---|
| Molecular Weight |
268.26
|
| Exact Mass |
268.074
|
| CAS # |
7478-60-6
|
| PubChem CID |
344546
|
| Appearance |
White to off-white solid powder
|
| Density |
1.353g/cm3
|
| Boiling Point |
446.6ºC at 760 mmHg
|
| Melting Point |
177-178ºC
|
| Flash Point |
169.4ºC
|
| Index of Refraction |
1.651
|
| LogP |
3.174
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
20
|
| Complexity |
409
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
IPRIGHIBTRMTDP-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C16H12O4/c1-19-11-7-8-12-13(9-11)20-16(15(18)14(12)17)10-5-3-2-4-6-10/h2-9,18H,1H3
|
| Chemical Name |
3-hydroxy-7-methoxy-2-phenylchromen-4-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
|---|
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.7277 mL | 18.6386 mL | 37.2773 mL | |
| 5 mM | 0.7455 mL | 3.7277 mL | 7.4555 mL | |
| 10 mM | 0.3728 mL | 1.8639 mL | 3.7277 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
